Literature DB >> 32492830

Relationships between Pulmonary Hypertension Risk, Clinical Profiles, and Outcomes in Dilated Cardiomyopathy.

Ewa Dziewięcka1, Sylwia Wiśniowska-Śmiałek1, Aleksandra Karabinowska1, Katarzyna Holcman1, Matylda Gliniak2, Mateusz Winiarczyk2, Arman Karapetyan2, Monika Kaciczak2, Piotr Podolec1, Magdalena Kostkiewicz1, Marta Hlawaty1, Agata Leśniak-Sobelga1, Paweł Rubiś1.   

Abstract

Pulmonary hypertension (PH) in patients with heart failure (HF) contributes to a poorer prognosis. However, in those with dilated cardiomyopathy (DCM), the true prevalence and role of PH is unclear. Therefore, this study aimed to analyze the profile of DCM patients at various levels of PH risk, determined via echocardiography, and its impact on outcomes. The 502 DCM in- and out-patient records were retrospectively analyzed. Information on patient status was gathered after 45.9 ± 31.3 months. Patients were divided into 3 PH-risk groups based on results from echocardiography measurements: low (L, n = 239, 47.6%), intermediate (I, n = 153, 30.5%), and high (H, n = 110, 21.9%). Symptom duration, atrial fibrillation, ventricular tachyarrhythmia, ejection fraction, right atrial area, and moderate or severe mitral regurgitation were found to be independently associated with PH risk. During the follow-up period, 83 (16.5%) DCM patients died: 29 (12.1%) in L, 31 (20.3%) in I, and 23 (20.9%) in H. L-patients had a significantly lower risk of all-cause death (L to H: HR 0.55 (95%CI 0.32-0.98), p = 0.01), while no differences in prognosis were found between I and H. In conclusion, over one in five DCM patients had a high PH risk, and low PH risk was associated with better prognoses.

Entities:  

Keywords:  dilated cardiomyopathy; echocardiography; pulmonary hypertension risk

Year:  2020        PMID: 32492830     DOI: 10.3390/jcm9061660

Source DB:  PubMed          Journal:  J Clin Med        ISSN: 2077-0383            Impact factor:   4.241


  2 in total

1.  Clinical Utility and Validation of the Krakow DCM Risk Score-A Prognostic Model Dedicated to Dilated Cardiomyopathy.

Authors:  Ewa Dziewięcka; Mateusz Winiarczyk; Sylwia Wiśniowska-Śmiałek; Aleksandra Karabinowska-Małocha; Matylda Gliniak; Jan Robak; Monika Kaciczak; Przemysław Leszek; Małgorzata Celińska-Spodar; Marcin Dziewięcki; Paweł Rubiś
Journal:  J Pers Med       Date:  2022-02-08

2.  Lack of Relationship between Fibrosis-Related Biomarkers and Cardiac Magnetic Resonance-Assessed Replacement and Interstitial Fibrosis in Dilated Cardiomyopathy.

Authors:  Paweł Rubiś; Ewa Dziewięcka; Magdalena Szymańska; Robert Banyś; Małgorzata Urbańczyk-Zawadzka; Maciej Krupiński; Małgorzata Mielnik; Sylwia Wiśniowska-Śmiałek; Aleksandra Karabinowska; Piotr Podolec; Mateusz Winiarczyk; Matylda Gliniak; Monika Kaciczak; Jan Robak; Arman Karapetyan; Ewa Wypasek
Journal:  Cells       Date:  2021-05-23       Impact factor: 6.600

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.